Soleno Therapeutics, Inc. Q3 2025 Earnings Recap

SLNO Q3 2025 November 5, 2025

Get alerts when SLNO reports next quarter

Soleno Therapeutics delivered exceptional third quarter results, with net revenues more than doubling to $66 million, culminating in a positive net income of $26 million as VYKAT XR establishes itself in the market as a crucial treatment for Prader-Willi syndrome (PWS).

Earnings Per Share Beat

$0.47 vs $0.06 est.

+717.4% surprise

Revenue Miss

66018000 vs 88547000 est.

-25.4% surprise

Market Reaction

1-Day -26.59%

5-Day -27.47%

30-Day -20.99%

See SLNO alongside your other holdings

Add to your portfolio — free

Key Takeaways

Achieved over 764 active patients on VYKAT XR six months post-launch, signaling strong market adoption.
Total net revenue surged more than 100% from Q2, highlighting robust growth momentum.
Despite a temporary disruption from a short seller report, patient engagement initiatives led to a rebound in therapy initiation as awareness and education advance.
Ongoing preparations for a marketing authorization application in the EU could significantly expand the addressable market for VYKAT XR.
Discontinuation rates remain below expectations, reflecting manageable safety concerns and effective patient management strategies.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit SLNO on AllInvestView.